<DOC>
	<DOC>NCT02637557</DOC>
	<brief_summary>The objectives of this study are to evaluate the safety, efficacy, and dose-response relationship of IW-3718 administered orally to patients who have GERD and continue to experience GERD symptoms while receiving once-daily (QD), standard-dose PPIs</brief_summary>
	<brief_title>A Randomized, Double-blind, Placebo-controlled,Trial of IW-3718 for 8 Weeks in Patient With Symptomatic GERD</brief_title>
	<detailed_description>This study is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, 8-week study, consisting of 3 distinct periods: a screening period, pretreatment period, and treatment period. The study will enroll patients who have GERD and continue to experience GERD symptoms while receiving QD, standard-dose PPI therapy. Eligible patients will continue to take their PPI and will be randomized to placebo or to one of three doses of study drug.</detailed_description>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<criteria>Patient is an ambulatory, communitydwelling male or nonpregnant female and is at least 18 years old at the Screening Visit. Lactating females must agree not to breastfeed. Patient has a diagnosis of GERD and reports experiencing GERD symptoms (heartburn or regurgitation) on â‰¥ 4 days per week during the 8 weeks before the Screening Visit while taking standard QD PPI therapy. Patient may not meet any of the excluded conditions specified in the protocol Patient has any alarm symptoms including but not limited to GI bleeding, anemia, vomiting, dysphagia, or unexpected weight loss any time during the Screening or Pretreatment Periods Patient has a history of clinically significant hypersensitivity or allergies to any of the excipients contained in the study medication (active or placebo).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>